Nar H - Search Results

1

Potent cholesteryl ester transfer protein inhibitors of reduced lipophilicity: 1,1'-spiro-substituted hexahydrofuroquinoline derivatives.

Trieselmann T, Wagner H, Fuchs K, Hamprecht D, Berta D, Cremonesi P, Streicher R, Luippold G, Volz A, Markert M, Nar H. Trieselmann T, et al. Among authors: nar h. J Med Chem. 2014 Nov 13;57(21):8766-76. doi: 10.1021/jm500431d. Epub 2014 Oct 27. J Med Chem. 2014. PMID: 25265559

2

Repaglinide and related hypoglycemic benzoic acid derivatives.

Grell W, Hurnaus R, Griss G, Sauter R, Rupprecht E, Mark M, Luger P, Nar H, Wittneben H, Müller P. Grell W, et al. Among authors: nar h. J Med Chem. 1998 Dec 17;41(26):5219-46. doi: 10.1021/jm9810349. J Med Chem. 1998. PMID: 9857091

3

Structure-based design of novel potent nonpeptide thrombin inhibitors.

Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W. Hauel NH, et al. Among authors: nar h. J Med Chem. 2002 Apr 25;45(9):1757-66. doi: 10.1021/jm0109513. J Med Chem. 2002. PMID: 11960487

4

Synthesis and structure-activity relationships of 6,7-benzomorphan derivatives as use-dependent sodium channel blockers for the treatment of stroke.

Grauert M, Bechtel WD, Weiser T, Stransky W, Nar H, Carter AJ. Grauert M, et al. Among authors: nar h. J Med Chem. 2002 Aug 15;45(17):3755-64. doi: 10.1021/jm020875j. J Med Chem. 2002. PMID: 12166948

5

Heterocyclic thrombin inhibitors. Part 1: design and synthesis of amidino-phenoxy quinoline derivatives.

Ries UJ, Priepke HW, Hauel NH, Haaksma EE, Stassen JM, Wienen W, Nar H. Ries UJ, et al. Among authors: nar h. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2291-5. doi: 10.1016/s0960-894x(03)00442-6. Bioorg Med Chem Lett. 2003. PMID: 12824020

6

Heterocyclic thrombin inhibitors. Part 2: quinoxalinone derivatives as novel, potent antithrombotic agents.

Ries UJ, Priepke HW, Hauel NH, Handschuh S, Mihm G, Stassen JM, Wienen W, Nar H. Ries UJ, et al. Among authors: nar h. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2297-302. doi: 10.1016/s0960-894x(03)00443-8. Bioorg Med Chem Lett. 2003. PMID: 12824021

7

8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes.

Eckhardt M, Langkopf E, Mark M, Tadayyon M, Thomas L, Nar H, Pfrengle W, Guth B, Lotz R, Sieger P, Fuchs H, Himmelsbach F. Eckhardt M, et al. Among authors: nar h. J Med Chem. 2007 Dec 27;50(26):6450-3. doi: 10.1021/jm701280z. Epub 2007 Dec 1. J Med Chem. 2007. PMID: 18052023

8

3,5-Dihydro-imidazo[4,5-d]pyridazin-4-ones: a class of potent DPP-4 inhibitors.

Eckhardt M, Hauel N, Himmelsbach F, Langkopf E, Nar H, Mark M, Tadayyon M, Thomas L, Guth B, Lotz R. Eckhardt M, et al. Among authors: nar h. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3158-62. doi: 10.1016/j.bmcl.2008.04.075. Epub 2008 May 1. Bioorg Med Chem Lett. 2008. PMID: 18485703

9

Ligand bioactive conformation plays a critical role in the design of drugs that target the hepatitis C virus NS3 protease.

LaPlante SR, Nar H, Lemke CT, Jakalian A, Aubry N, Kawai SH. LaPlante SR, et al. Among authors: nar h. J Med Chem. 2014 Mar 13;57(5):1777-89. doi: 10.1021/jm401338c. Epub 2013 Nov 8. J Med Chem. 2014. PMID: 24144444

10

An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo.

Schiele F, Park J, Redemann N, Luippold G, Nar H. Schiele F, et al. Among authors: nar h. J Mol Biol. 2014 Feb 20;426(4):843-52. doi: 10.1016/j.jmb.2013.11.011. Epub 2013 Nov 16. J Mol Biol. 2014. PMID: 24252255

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

92 results

Search Page